

**Freedom of Information Act 2000 – Request Reference FoI/24/159**  
**Severe Asthma Treatment**

**Information Requested:**

I am conducting analysis on the treatment of severe asthma in secondary care and kindly request your help.

I would be grateful if you could send me two outputs of data:

[a] From the electronic prescribing system the number of patients treated with specific medicines between the start of Oct 2023 to the end of Dec 2023, or the latest three-month period for which data is available. I have included a template below with details.

[b] From the hospital pharmacy database quantities of medicines used. See specification below and I would be grateful if this can be supplied in Excel or .csv format.

Please include data for all hospitals in the Health Board.

**[a] Data on numbers of patients from the electronic prescribing system**

Q1. How many patients were treated **in total, regardless of diagnosis**, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	
1.2 Dupilumab (Dupixent)	
1.3 Mepolizumab (Nucala)	
1.4 Omalizumab (Xolair)	
1.5 Reslizumab (Cinqaero)	
1.6 Tezepelumab (Tezspire)	

Q2. How many patients were treated for **severe asthma**, atopic dermatitis, CRwNP and other indications with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Severe asthma (please include all types or	Chronic rhinosinusitis with nasal polyps (CRwNP)	Atopic Dermatitis	Other

	references to asthma)			
2.1 Benralizumab (Fasenra)		N/A	N/A	N/A
2.2 Dupilumab (Dupixent)				
2.3 Mepolizumab (Nucala)			N/A	
2.4 Omalizumab (Xolair)			N/A	
2.5 Reslizumab (Cinqaero)		N/A	N/A	N/A
2.6 Tezepelumab (Tezspire)		N/A	N/A	N/A

Q3. How many patients were treated **by department** in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Respiratory departments	Dermatology departments	Other
3.1 Benralizumab (Fasenra)			
3.2 Dupilumab (Dupixent)			
3.3 Mepolizumab (Nucala)			
3.4 Omalizumab (Xolair)			
3.5 Reslizumab (Cinqaero)			
3.6 Tezepelumab (Tezspire)			

**[b] data on usage of medicines from the hospital pharmacy system**

Fields to include in the data extract from the hospital pharmacy database:

Field	
Calendar year	
Calendar month	
Name of Health Board / Trust	
Drug substance (INN name of drug)	
Drug product pack name	Virtual or actual product pack name
Quantity unit of measure (UOM)	e.g. tablet, mL, vial, the unit in which the quantity can be measured
Quantity issued	

Filters

- Time period: Jan 2019 to Feb 2024, or the latest available month
- Drugs to include:
  - Benralizumab (Fasenra)
  - Dupilumab (Dupixent)
  - Mepolizumab (Nucala)
  - Omalizumab (Xolair)
  - Reslizumab (Cinqaero)
  - Tezepelumab (Tezspire)

**Response Details:**

**In response to part [a]**

Cardiff and Vale University Health Board does not hold this information as it does not have an electronic prescribing system at present.

**In response to part [b]**

Please see the attached Excel documents. The data has been split due to the implementation of a new pharmacy system in August 2021.